Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476383 | 1.00 | HSD11B1 (0.51) | HSD11B1ALDH1A1TACR1SLC6A4POLB | |
| SCHEMBL11920965 | 1.00 | HSD11B1 (0.51) | HSD11B1ALDH1A1TACR1SLC6A4POLB | |
| SCHEMBL14342725 | 0.88 | ALDH1A1 (0.42) | HSD11B1ALDH1A1TACR1SLC6A4CACNA1G | |
| SCHEMBL2790782 | 0.81 | HSD11B1 (0.48) | HSD11B1TACR1SLC6A4POLBLMNA | |
| SCHEMBL5484210 | 0.78 | SLC6A4 (0.41) | HSD11B1ALDH1A1TACR1SLC6A4CACNA1G | |
| SCHEMBL11920268 | 0.78 | SLC6A4 (0.41) | HSD11B1ALDH1A1TACR1SLC6A4CACNA1G | |
| SCHEMBL5484212 | 0.78 | SLC6A4 (0.41) | HSD11B1ALDH1A1TACR1SLC6A4CACNA1G | |
| SCHEMBL11920683 | 0.76 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL11920701 | 0.74 | HSD11B1 (0.52) | HSD11B1OPRM1 | |
| SCHEMBL11822485 | 0.72 | HSD11B1 (0.44) | HSD11B1ALDH1A1TACR1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772296-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2044004-B1 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | HSD3B1, HSD17B1, HSD3B2 | HSD11B1 4/4885ALDH1A1 330/4885TACR1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.